Muscle-specific nucleic acid regulatory elements and methods and use thereof
The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.
1. A nucleic acid expression cassette comprising at least one nucleic acid regulatory element for enhancing muscle-specific gene expression operably linked to a promoter and a heterologous transgene, wherein said nucleic acid regulatory element comprises the sequence set forth in SEQ ID NO:10, or a functional fragment of SEQ ID NO:10, wherein said functional fragment comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40 and SEQ ID NO:41.
2. The nucleic acid expression cassette according to claim 1 , wherein the promoter is a muscle-specific promoter.
3. The nucleic acid expression cassette according to claim 1 , wherein the promoter is the promoter from the desmin (DES) gene or the SPc5-12 promoter.
4. The nucleic acid expression cassette according to claim 1 , wherein the promoter is the human DES 1.0 kb promoter having SEQ ID NO:47, the human DES 1.4 kb promoter having SEQ ID NO:48 or the SPc5-12 promoter having SEQ ID NO:53.
5. The nucleic acid expression cassette according to claim 1 , wherein the transgene encodes a therapeutic protein, an immunogenic protein, or a structural protein.
6. The nucleic acid expression cassette according to claim 1 , wherein the transgene encodes dystrophin, a sarcoglycan, alpha-glucosidase or myotubularin 1.
7. The nucleic acid expression cassette according to claim 1 , wherein the transgene encodes a codon-optimized version of alpha-glucosidase or myotubularin 1.
8. The nucleic acid expression cassette according to claim 1 , wherein the transgene is codon-optimized version of the human alpha-glucosidase gene having SEQ ID NO:50 or a codon-optimized version of the human myotubularin 1 gene having SEQ ID NO:52.
9. A vector comprising at least one nucleic acid regulatory element for enhancing muscle-specific gene expression operably linked to a promoter and a heterologous transgene, wherein said nucleic acid regulatory element comprises the sequence set forth in SEQ ID NO:10, or a functional fragment of SEQ ID NO:10, wherein said functional fragment comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40 and SEQ ID NO:41.
10. The vector according to claim 9 , which is a viral vector.
11. The vector according to claim 9 , which is an adeno-associated viral vector.
12. A pharmaceutical composition comprising a nucleic acid expression cassette according to claim 1 , or a vector comprising the nucleic acid expression cassette, and a pharmaceutically acceptable carrier.
13. The nucleic acid expression cassette according to claim 1 , wherein the nucleic acid regulatory element enhances skeletal muscle-specific gene expression.
14. The nucleic acid expression cassette according to claim 1 , wherein the nucleic acid regulatory element has a maximal length of 600 nucleotides.
15. The vector according to claim 9 , wherein the nucleic acid regulatory element enhances skeletal muscle-specific gene expression.
16. The vector according to claim 9 , wherein the nucleic acid regulatory element has a maximal length of 600 nucleotides.